{"name":"Melbourne Theranostic Innovation Centre","slug":"melbourne-theranostic-innovation-centre","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"68Ga-NTA-476","genericName":"68Ga-NTA-476","slug":"68ga-nta-476","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"68Ga-NTA-476","genericName":"68Ga-NTA-476","slug":"68ga-nta-476","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1iQXZmM2hUZHFibVdlSjNyMEFDUWRPeTNsWTN5NWRPQ2luTFgxU3lMQ2haNGh5TUFYUTdLLVNzbk1wclJWdTdmcXBHTjZaVFFTVXdLdHBfZkoxQWJORlZwWW5jbw?oc=5","date":"2025-09-09","type":"trial","source":"aapnews.aap.com.au","summary":"Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis - aapnews.aap.com.au","headline":"Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNbURvVTZ6V0tMNWhVWDhkU3R6cWl1Vm9WdjBWQkloSlZqVzVfZklyYTZpY0RqdHlwNnNYOW5Wbzd3UUtBR0xYRXJRUkVNcF9sc3AwUW1UTWpQYUtkUVN5aGozMmtaOEx0cE9EUzVRZV9MV0pUZ0NUNlNSSEJ1THdoam9vSmVMS0doQV9mRUtPZlFYZWhfMjdNdVhuVTIwNEwxamxDMm1FMUFDamxwZGhzVE5wWC10UVNUekthdk95a1E0SnBzM2piTXNSTjd6TVNsaDE0cUcxbXFKanc2ZVB0ZUNsWjFuZGktbFVabFBuNmZNNk5feDVXb0RrbjVBV1lnV0E?oc=5","date":"2025-04-02","type":"trial","source":"PR Newswire","summary":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma - PR Newswire","headline":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}